Business Description
Regenerx Biopharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886X3061
Description
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 99.98 | |||||
14-Day RSI | 93.11 | |||||
3-1 Month Momentum % | 100 | |||||
6-1 Month Momentum % | 100 | |||||
12-1 Month Momentum % | 200 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -1084.21 | |||||
OCF Margin % | -1084.21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.18 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Revenue | 3.17 | |||||
EV-to-FCF | -0.29 | |||||
Earnings Yield (Greenblatt) % | -555.56 | |||||
FCF Yield % | -82400 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RGRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regenerx Biopharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.076 | ||
| EPS (TTM) ($) | -0.903 | ||
| Beta | 293.5738 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 241.18 | ||
| Volatility % | 80223.17 | ||
| 14-Day RSI | 93.11 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0006 | ||
| 12-1 Month Momentum % | 200 | ||
| 52-Week Range ($) | 0.0002 - 0.163 | ||
| Shares Outstanding (Mil) | 1.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regenerx Biopharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regenerx Biopharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2023-10-18 | 0.97 (+0.00%) |
Show
Entries
Regenerx Biopharmaceuticals Inc Frequently Asked Questions
What is Regenerx Biopharmaceuticals Inc(RGRX)'s stock price today?
The current price of RGRX is $0.00. The 52 week high of RGRX is $0.16 and 52 week low is $0.00.
When is next earnings date of Regenerx Biopharmaceuticals Inc(RGRX)?
The next earnings date of Regenerx Biopharmaceuticals Inc(RGRX) is .
Does Regenerx Biopharmaceuticals Inc(RGRX) pay dividends? If so, how much?
Regenerx Biopharmaceuticals Inc(RGRX) does not pay dividend.
Guru Commentaries on OTCPK:RGRX
No articles.
Press Release
Articles on Regenerx Biopharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers